Ignite Creation Date:
2024-05-05 @ 7:02 PM
Last Modification Date:
2024-10-26 @ 9:41 AM
Study NCT ID:
NCT00591851
Status:
COMPLETED
Last Update Posted:
2023-09-25
First Post:
2007-12-26
Brief Title:
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide AC Followed By Paclitaxel With Trastuzumab in HER2 NEU-Amplified Breast Cancer Feasibility
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Organization Data
Organization:
Memorial Sloan Kettering Cancer Center
Class:
OTHER
Study ID:
04-126
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |
| Amgen | INDUSTRY |